LEPU BIO(02157.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at CNY 27.39 million, YoY decrease of 34.38%

August 19, 2026, LEPU BIO(02157.HK) released its Interim Report for the period ended December 31, 2026, Total Revenue stood at CNY 522.41 million, increased by 12.12% YoY; Net Profit stood at CNY 24.85 million, YoY decrease of 15.2%; Profit Attributable to Shareholders stood at CNY 27.39 million, YoY decrease of 34.38%; Basic Earnings Per Share (EPS) stood at CNY cents 2.
In terms of profitability, LEPU BIO Gross Profit changed from CNY 438.54 million in the same period last year to CNY 475.38 million in the current period, increased by CNY 36.84 million; gross profit margin changed from 94.12% in the same period last year to 91% in the current period, decreased by 3.12 percentage points; net profit changed from CNY 29.3 million in the same period last year to CNY 24.85 million in the current period, decreased by CNY 4.45 million; net profit margin changed from 6.29% in the same period last year to 4.76% in the current period, decreased by 1.53 percentage points.
In terms of earnings quality, LEPU BIO Operating Profit changed from CNY 42.98 million in the same period last year to CNY 41.38 million in the current period, decreased by CNY 1.6 million; Operating Profit Margin changed from 9.22% in the same period last year to 7.92% in the current period, decreased by 1.3 percentage points.
In terms of financial soundness, LEPU BIO Debt-to-Asset Ratio changed from 69.86% in the same period last year to 56.18% in the current period, decreased by 13.68 percentage points; Total Equity changed from CNY 711.795 million in the same period last year to CNY 1.387 billion in the current period, increased by CNY 675.36 million; Current Liabilities changed from CNY 1.11 billion in the same period last year to CNY 1.02 billion in the current period, decreased by CNY 94.15 million; Quick Ratio changed from 0.59 in the same period last year to 1.07 in the current period, increased by 0.48 percentage points.
In terms of R&D investment focus, LEPU BIO R&D Expenses changed from CNY 202.24 million in the same period last year to CNY 208.26 million in the current period, increased by CNY 6.02 million; R&D to Total Revenue Ratio changed from 43.41% in the same period last year to 39.87% in the current period, decreased by 3.54 percentage points.
By the close of trading on August 19, 2026, LEPU BIO(02157) saw a loss of 3.66% in its share price, closing at HKD 4.085. The full-day turnover stood at HKD 32.13 million, with the latest market capitalization at HKD 7.37 billion.

NewTimeSpace Disclaimer:All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.